Business Context and Reporting Period
This Form 8-K is a current report filed by Bristol-Myers Squibb Company on November 17, 2025. The filing addresses "Other Events" (Item 8.01) regarding the early participation results, amendment, and early settlement of previously announced cash tender offers to purchase the company's outstanding notes.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, or overall liquidity. The document focuses exclusively on the mechanics of a debt tender offer. The following securities are registered and subject to the tender offers:
- 1.750% Notes due 2035 (BMY35)
- 2.973% Notes due 2030 (BMY/30)
- 3.363% Notes due 2033 (BMY/33)
- 3.857% Notes due 2038 (BMY/38)
- 4.289% Notes due 2045 (BMY/45)
- 4.581% Notes due 2055 (BMY/55)
Material Changes
The primary material change reported is the early settlement of the cash tender offers announced on November 3, 2025. The company issued a press release on November 17, 2025, detailing early participation results and an amendment to the offers. A subsequent press release on November 18, 2025, announced the accepted amounts and pricing terms. Specific financial figures regarding the volume of notes tendered or the total settlement amount are not included in the body of this filing but are referenced in attached Exhibits 99.1 and 99.2.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, earnings outlook, or management commentary regarding operational performance. The primary risk disclosure relates to the legal validity of the offers, stating they are void in jurisdictions where prohibited and are not an offer to purchase in any jurisdiction where such an offer is unlawful.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated Nov 17, 2025) for specific early participation percentages and the nature of the offer amendment.
- Review Exhibit 99.2 (Press Release dated Nov 18, 2025) for the final accepted amounts and specific pricing terms of the settlement.
- Verify the impact of the debt reduction on the company's total leverage ratio using the settlement figures from the exhibits.
- Confirm the status of the remaining outstanding notes for each series listed in the filing.